Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 + Anlotinib in Advanced Solid Tumors
NCT03897283Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of benmelstobart in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03897283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897283.